BeOne Medicines (ONC) Capital Expenditures (2015 - 2026)
BeOne Medicines' (ONC) quarterly Capital Expenditures came in at $43.2 million in Q1 2026, down 27.93% year-on-year from $60.0 million in Q1 2025, and up 147.51% on a QoQ basis from -$91.0 million in Q4 2025.
BeOne Medicines (ONC) Capital Expenditures (2015 - 2026) Analysis & Trends
BeOne Medicines (ONC) has 12 years of Capital Expenditures data on file, last reported at $43.2 million in Q1 2026.
- On a quarterly basis, Capital Expenditures fell 27.93% year-over-year to $43.2 million in Q1 2026; TTM through Mar 2026 was $40.5 million, a 254.35% increase from a year earlier, with the FY2025 full-year figure at $57.3 million, down 18.53% from the prior year.
- Capital Expenditures for Q1 2026 stood at $43.2 million, up from -$91.0 million in the prior quarter.
- Over the last five years, Capital Expenditures for ONC reached as high as $183.0 million in Q2 2023 and fell as low as -$139.4 million in Q3 2023.
- Historically, Capital Expenditures has averaged $34.6 million across 5 years, with a median of $43.2 million in 2026.
- Across the five-year window, Capital Expenditures surged 1251.36% in 2023 and sank 1719.59% in 2025, its largest moves.
- Year by year, Capital Expenditures stood at $121.4 million in 2022, then sank by 113.03% to -$15.8 million in 2023, then soared by 68.35% to -$5.0 million in 2024, then sank by 1719.59% to -$91.0 million in 2025, then jumped by 147.51% to $43.2 million in 2026.
- Per Business Quant data, the three most recent Capital Expenditures figures were $43.2 million in Q1 2026, -$91.0 million in Q4 2025, and $48.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 43.25 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 786,000.00 |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | 21.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.25 Mn |
| Mar 31, 2026 | 43.25 Mn |
| Dec 31, 2025 | -91.03 Mn |
| Dec 31, 2025 | -91.03 Mn |
| Sep 30, 2025 | 48.08 Mn |
| Sep 30, 2025 | 48.08 Mn |
| Jun 30, 2025 | 40.22 Mn |
| Jun 30, 2025 | 40.22 Mn |
| Mar 31, 2025 | 60.01 Mn |
| Mar 31, 2025 | 60.01 Mn |
| Dec 31, 2024 | -5.00 Mn |
| Dec 31, 2024 | -5.00 Mn |
| Sep 30, 2024 | -40.25 Mn |
| Sep 30, 2024 | -40.25 Mn |
| Jun 30, 2024 | -41.01 Mn |
| Jun 30, 2024 | -41.01 Mn |
| Mar 31, 2024 | 156.58 Mn |
| Mar 31, 2024 | 156.58 Mn |
| Dec 31, 2023 | -15.81 Mn |
| Dec 31, 2023 | -15.81 Mn |